EU-US trade deal could add up to $19 billion in pharma industry costs, analysts say

A new EU-US trade deal introduces a 15% tariff on branded European pharmaceutical imports to the U.S., a sector historically exempt from duties, potentially costing the industry $13 billion to $19 billion annually. While these costs could raise consumer prices, companies like Roche and Sanofi are implementing mitigation strategies such as increased U.S. inventories. Despite the new levies, shares of major pharmaceutical companies like Sanofi, Roche, and Sandoz saw modest gains, suggesting market relief that the tariffs were not higher or that companies can absorb the impact.

Analysis

A prospective EU-US trade agreement is set to introduce a 15% tariff on branded pharmaceuticals, a significant policy shift for a sector historically exempt from such duties. Analysts estimate this could impose new annual costs on the industry ranging from $13 billion to $19 billion, potentially impacting consumer prices. The EU's position as the source of approximately 60% of all US pharmaceutical imports underscores the tariff's broad reach. Despite these new costs, the 15% rate is substantially lower than the 200% tariff previously threatened by the US administration, a factor that likely contributed to a relief rally, with shares in Sanofi, Roche, and Sandoz closing up between 0.5% and 1%. Major pharmaceutical firms are already implementing mitigation strategies; Roche is increasing its U.S. inventories to prevent supply disruptions, while Sanofi is divesting a US manufacturing facility to Thermo Fisher, signaling a strategic adjustment. Analysts from UBS and ING express cautious optimism that further tariffs are unlikely, but stress that uncertainty will remain until the trade deal is officially signed and specific details, such as which generic drugs are exempted, are clarified.

Key Decisions for Investors

• Investors should closely monitor the effectiveness of corporate mitigation strategies, such as Roche's inventory stockpiling and Sanofi's supply chain adjustments, as these will be critical determinants of margin pressure.
• The positive market reaction suggests the 15% tariff was a better-than-feared outcome, but it is prudent to remain cautious given the deal is not yet finalized and key details on generic drug exemptions are still pending.
• Evaluate exposure to EU pharmaceutical companies with high revenue concentration from the U.S. and consider the relative advantage for firms with established U.S. manufacturing footprints or those like Thermo Fisher that may benefit from industry restructuring.